Vol 8, No 1 (2022)
Review paper
Published online: 2022-04-01

open access

Page views 1862
Article views/downloads 25
Get Citation

Connect on Social Media

Connect on Social Media

Diagnostyka obrazowa w obserwacji chorych na czerniaki skóry i błon śluzowych

Bożena Józefa Cybulska-Stopa1, Grażyna Kamińska-Winciorek2, Piotr Rutkowski3
Forum Dermatologicum 2022;8(1):30-35.


W ostatnich latach wyniki leczenia chorych na czerniaki uległy znacznej poprawie. Wiąże się to przede wszystkim z rozwojem nowych metod terapeutycznych, ale również z rozwojem badań obrazowych i rozpoznaniem nawrotu choroby na wczesnym etapie. Dzięki wczesnemu rozpoznaniu nawrotu choroby nowotworowej można zastosować właściwą terapię, która w wielu przypadkach może doprowadzić do całkowitego wyleczenia.

Article available in PDF format

View PDF (Polish) Download PDF file


  1. Dinnes J, Ferrante di Ruffano L, Takwoingi Y, et al. Cochrane Skin Cancer Diagnostic Test Accuracy Group. Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma. Cochrane Database Syst Rev. 2019; 7: CD012806.
  2. Rutkowski P, Wysocki PJ, Kozak K, et al. Expert recommendations on diagnostic-therapeutic management of melanoma patients. Oncol Clin Pract. Oncol Clin Pract. .
  3. Danielsen M, Højgaard L, Kjær A, et al. Positron emission tomography in the follow-up of cutaneous malignant melanoma patients: a systematic review. Am J Nucl Med Mol Imaging. 2013; 4(1): 17–28.
  4. Nijhuis AAG, Dieng M, Khanna N, et al. False-Positive Results and Incidental Findings with Annual CT or PET/CT Surveillance in Asymptomatic Patients with Resected Stage III Melanoma. Ann Surg Oncol. 2019; 26(6): 1860–1868.
  5. Koskivuo I, Kemppainen J, Giordano S, et al. Whole body PET/CT in the follow-up of asymptomatic patients with stage IIB-IIIB cutaneous melanoma. Acta Oncol. 2016; 55(11): 1355–1359.
  6. Vensby PH, Schmidt G, Kjær A, et al. The value of FDG PET/CT for follow-up of patients with melanoma: a retrospective analysis. Am J Nucl Med Mol Imaging. 2017; 7(6): 255–262.
  7. Morton RL, Craig JC, Thompson JF. The role of surveillance chest X-rays in the follow-up of high-risk melanoma patients. Ann Surg Oncol. 2009; 16(3): 571–577.
  8. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Cutaneous melanoma. https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf (23.08.2021).
  9. Francken AB, Bastiaannet E, Hoekstra HJ. Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol. 2005; 6(8): 608–621.
  10. Francken AB, Accortt NA, Shaw HM, et al. Follow-up schedules after treatment for malignant melanoma. Br J Surg. 2008; 95(11): 1401–1407.
  11. Trotter SC, Sroa N, Winkelmann RR, et al. A Global Review of Melanoma Follow-up Guidelines. J Clin Aesthet Dermatol. 2013; 6(9): 18–26.
  12. Atkins MB, Long GV, Warneke CL, et al. Unraveling the prognostic heterogeneity in patients with advanced melanoma between Australia (OZ) and the United States (US): Preliminary report of the PHAMOUS study. J Clin Oncol 28:15s, 2010 (suppl; abstr. ; 8516.
  13. Francken AB, Shaw HM, Accortt NA, et al. Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines. Ann Surg Oncol. 2007; 14(6): 1924–1933.
  14. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med. 2004; 351(10): 998–1012.
  15. Bassères N, Grob JJ, Richard MA, et al. Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France. Dermatology. 1995; 191(3): 199–203.
  16. Goggins WB, Tsao H. A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors. Cancer. 2003; 97(3): 639–643.
  17. DiFronzo LA, Wanek LA, Elashoff R, et al. Increased incidence of second primary melanoma in patients with a previous cutaneous melanoma. Ann Surg Oncol. 1999; 6(7): 705–711.
  18. Faries MB, Thompson JF, Cochran AJ, et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med . 2017; 376(12): 2211–2222.
  19. Shumate CR, Urist MM, Maddox WA. Melanoma recurrence surveillance. Patient or physician based? Ann Surg. 1995; 221(5): 566–9; discussion 569.
  20. Meyers MO, Yeh JJ, Frank J, et al. Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging. Ann Surg Oncol. 2009; 16(4): 941–947.
  21. Weiss M, Loprinzi CL, Creagan ET, et al. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA. 1995; 274(21): 1703–1705.
  22. Ward WH, Farma JM. editors. Cutaneous Melanoma: Etiology and Therapy [Internet] . Codon Publ. 2017: Codon.
  23. Garbe C, Paul A, Kohler-Späth H, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol. 2003; 21(3): 520–529.
  24. Podlipnik S, Carrera C, Sánchez M, et al. Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: A prospective cohort study. J Am Acad Dermatol. 2016; 75: 516.
  25. Romano E, Scordo M, Dusza SW, et al. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol. 2010; 28(18): 3042–3047.
  26. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996; 14(1): 7–17.
  27. DeRose ER, Pleet A, Wang W, et al. Utility of 3-year torso computed tomography and head imaging in asymptomatic patients with high-risk melanoma. Melanoma Res. 2011; 21(4): 364–369.
  28. Turner RM, Dieng M, Khanna N, et al. Performance of Long-Term CT and PET/CT Surveillance for Detection of Distant Recurrence in Patients with Resected Stage IIIA-D Melanoma. Ann Surg Oncol. 2021; 28(8): 4561–4569.